The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The safety and efficacy of zilovertamab vedotin in R/R MCL post-BTKi
Ingrid Glimelius, MD, PhD, Uppsala University, Uppsala, Sweden, comments on the safety and efficacy of zilovertamab vedotin, an antibody-drug conjugate that targets ROR1, in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) post-BTK inhibitor (BTKi). She reports a 40% overall response rate and manageable side effects, highlighting the potential of this agent for patients who have become CD20-negative after bispecific antibody therapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yes, that’s a study on relapsed/refractory mantle cell lymphoma patients, post-BTK inhibitors. And it’s a study of 40 patients, where we look into monotherapy with zilovertamab vedotin. And zilovertamab vedotin is an ADC. It’s an antibody against ROR1 with MMAE, a chemotherapy bound to it. And we treat the patients every third week with it. And 40 patients with an overall response rate of 40%...
Yes, that’s a study on relapsed/refractory mantle cell lymphoma patients, post-BTK inhibitors. And it’s a study of 40 patients, where we look into monotherapy with zilovertamab vedotin. And zilovertamab vedotin is an ADC. It’s an antibody against ROR1 with MMAE, a chemotherapy bound to it. And we treat the patients every third week with it. And 40 patients with an overall response rate of 40%. So it was feasible to give and there were no treatment-related deaths. There were some side effects, gastrointestinal toxicity, but rather mild. So I think that is an option for patients that, for example, become CD20 negative post-bispecific antibody because it’s another target, it’s ROR1.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Janssen: Speakers Bureau; AstraZeneca: Consultancy; Takeda: Honoraria, Other: Research Grant/Funding.
